AI驱动的药物发现引擎 - Isomorphic Labs 正在构建一个药物设计引擎，旨在为不同疾病领域和适应症设计新的分子，甚至适用于不同的药物形式[2] - 该引擎由一系列AI模型驱动，需要大约六个类似AlphaFold的突破性技术共同作用[3] - 这些模型包括预测蛋白质结构、分子结合强度以及药物安全性和吸收性的能力[3][6] 传统药物发现的变革 - 传统药物设计是迭代的，耗时且成本高昂，而Isomorphic Labs 正在将这一过程转移到虚拟世界，在计算机上进行设计和测试，从而缩短时间并提高效率[8][9][10] - 通过在计算机上进行多次迭代，选择最佳结果进行实验室测试，从而跳过步骤，更快地获得更好的结果[10] 模型能力与挑战 - AlphaFold 已经解决了蛋白质折叠问题，但仍需要提高模型的准确性，并理解分子如何与身体的不同部分相互作用[11][12][13] - 分子空间巨大（约10的60次方），需要生成模型和搜索过程来有效地搜索整个空间，从而减少需要实验室测试的分子数量[15][16] 数据策略与质量 - 机器学习依赖于高质量的数据，Isomorphic Labs 拥有全面的数据战略，利用公共数据、历史数据以及专门为机器学习模型创建的湿实验室数据[24][25] - 公司在理解、摄取、清理数据以及从中提取信号方面投入了大量精力[26] 通用性与可重用性 - Isomorphic Labs 专注于构建通用的技术，可以应用于任何靶点、任何疾病领域，甚至任何不同的药物形式[27][28] - 通用模型更具挑战性，但可以创造针对长期未解决的问题的全新化学物质[30][31] 疾病领域重点 - 公司专注于免疫学和肿瘤学，因为这些领域的临床试验更易于处理，可以在更短的时间内完成，并且对患者的影响很大[33][34] - 目标是将癌症转变为一种慢性疾病，患者可以通过药物治疗获得正常的寿命，这可能在几年内实现[36][37] 模型能力与应用 - 这些模型可以应用于整个人类蛋白质组，并且由于神经网络模型运行速度快，可以并行分析数千个蛋白质[39] - 这改变了实验设计，因为在实验世界中，一次只能研究一个蛋白质[40] 合作与里程碑 - 与诺华和礼来等公司的合作非常密切，在一些具有挑战性的靶点上取得了良好的进展[44] - 在某些情况下，已经识别出与以前未知的蛋白质结合的首批化学物质[45] 未来展望 - 目标是在2-3年内将AI药物发现过程缩短至几个月，关键在于提高计算机实验结果的预测准确性[47][48][49] - 展望未来，AI工具可以帮助诊断疾病，并提供相应的药物治疗，从而对人类健康和疾病产生重大影响[50][51]

The mission statement of Isomporhic Labs is to solve all disease. Where are we with in that mission. Well, I think we're making good progress.We're building a kind of general platform to help tackle the understanding, really, of biology and the chemistry that you need to buy into that biology. And I think if it works out, we should be able to tackle many, many diseases. How should we think about where the time frame sits then in terms of Iso labs discovering an AI drug and then getting it into clinical tria ...

>> YOU ARE WATCHING BLOOMBERG TECH EUROPE. COMING UP, A. I.DISCOVERY COULD BE THE NEXT FRONTIER OF MEDICINE TO SPEEDING UP DEVELOPMENT. THE TECHNOLOGY PROMISES PLENTY BUT WILL IT DELIVER. WE SPEAK EXCLUSIVELY TO DENNIS HASSABIS THE NOBLE LAUREATE, WHOSE LONDON-BASED ISOMORPHIC LABS HAS THE AMBITION 'TO SOLVE ALL DISEASE.' THE MAN RESPONSIBLE FOR ALL OF ALPHABET’S CORE A. I. WORK AS HEAD OF GOBBLE DEEPMIND IS SETTING THE BAR HIGH FOR ISOMOPHIC.>> THE KIND OF HOLY GRAIL IS TO TACKLE CANCER. BUT WE’VE DONE IT ...

Our CEO @demishassabis, Chief AI Officer @maxjaderberg, and Head of Medicinal Drug Design @_rebecca_paul were featured on the latest episode of Bloomberg Tech Europe (@technology) to share how we're leveraging frontier AI in groundbreaking ways to reimagine drug discovery and advance human healthFollow the link learn more about what Iso does and our progress towards solving all disease: https://t.co/udCOQflCFD ...

Discovering new medicines takes years and is marred by an astronomical failure rate. The Nobel Prize-winning head of Alphabet’s AI lab says the technology will soon trim that time to under a year https://t.co/yMO6xfKz86 ...

Absci Inc. ABSI on Thursday collaborated with Oracle Corporation’s ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery.Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.Also Read: Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA’s Decision To End Animal TestingWith OCI, Absci has been able to acceler ...

Absci (NASDAQ:ABSI) on Thursday announced a collaboration with Oracle Cloud Infrastructure (NYSE:ORCL) and AMD (NASDAQ:AMD) to accelerate its AI-driven drug discovery efforts. As part of the partnership, the Vancouver, Washington-based biotech will use Oracle’s (NYSE:ORCL) AI infrastructure and AMD’s ( ...

Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costsAUSTIN, Texas and VANCOUVER, Washington, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Absci, a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastr ...

[Applause] Let's start with a small exercise. So to warm you up, I will have three questions to you. First of all, how many of you have used recently artificial intelligence.Okay. How many of you have used some kind of medicines le recently. Some of you.And how many of you know that AI can be used to find new drugs. Okay, great. Fantastic.So my name is Kamas Kazabel and today I will uncover like a hidden layers for you a world of medicines and how artificial intelligence can be used to find new drugs. But l ...

Company Overview - PreveCeutical Medical Inc. is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products [5] - The company has five research and development programs targeting diabetes, obesity, and other health issues, including dual gene therapy and non-addictive analgesic peptides [5] Leadership Appointment - BioGene Therapeutics Inc., a wholly owned subsidiary of PreveCeutical, appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025 [1][4] - Dr. Tavares has extensive experience in the biopharmaceutical industry, previously serving as President, CEO, and Founder of ChemoGenics BioPharma, and has a strong background in drug discovery and medicinal chemistry [2][3] Dr. Tavares' Contributions - Dr. Tavares has a PhD in Organic Chemistry and has led the development of significant drug candidates, including Trilaciclib and Lerociclib, demonstrating a successful track record in advancing drug candidates to clinical trials [3] - His appointment is expected to enhance BioGene's capabilities in drug discovery and product commercialization, benefiting both patients and investors [4] BioGene Therapeutics Inc. Overview - BioGene is focused on advancing innovative therapies in metabolic health and gene-based treatments, with a subsidiary in Australia that leverages a 43.5% R&D tax cashback incentive [6] - The company is engaged in research aimed at addressing the global diabetes and obesity crisis through gene therapy-based approaches [6]